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Reader’s guide to critical appraisal of cohort studies: 1.
Role and design
Paula A Rochon, Jerry H Gurwitz, Kathy Sykora, Muhammad Mamdani, David L Streiner,
Susan Garfinkel, Sharon-Lise T Normand, Geoffrey M Anderson
Cohort studies can provide valuable information unavailable from randomised trials, but readers
need to be alert to possible flaws
Valid evidence on the benefits and risks of healthcare
interventions is essential to rational decision making.
Randomised controlled trials are considered the best
method for providing evidence on efficacy. However,
they face important ethical and logistical constraints
and have been criticised for focusing on highly selected
populations and outcomes.1 2 Some of these problems
can be overcome by cohort studies. Cohort studies can
be thought of as natural experiments in which
outcomes are measured in real world rather than
experimental settings. They can evaluate large groups
of diverse individuals, follow them for long periods,
and provide information on a range of outcomes,
including rare adverse events. However, the promise of
cohort studies as a useful source of evidence needs to
be balanced against concerns about the validity of that
evidence.3 4
In this three paper series we will provide an
approach to the critical appraisal of cohort studies.
This article describes the role and design of cohort
studies and explains how selection bias can confound
the relation between the intervention and the outcome.
The second article will outline strategies for identifica-
tion and assessment of the potential for confounding,
and the third article describes statistical techniques that
can be used to deal with confounding. Each paper
defines a set of questions that, taken together, can pro-
vide readers with a systematic approach to critically
assessing evidence from cohort studies.
Randomised trial or cohort study?
Cohort studies are similar to randomised controlled
trials in that they compare outcomes in groups that did
and did not receive an intervention. The main
difference is that allocation of individuals is not by
chance. Table 1 gives some important similarities and
differences between the two types of study. Because
they are expensive and recruiting patients can be diffi-
cult, randomised controlled trials are generally short
term and used to determine efficacy in selected popu-
lations under strict conditions. Cohort studies can be
used to determine if the efficacy observed in
randomised trials translates into effectiveness in
broader populations and more realistic settings and to
provide information on adverse events and risks.5
Selection bias as a threat to validity
The internal validity of a study is defined as the extent
to which the observed difference in outcomes between
the two comparison groups can be attributed to the
intervention rather than other factors. The biggest
advantage of randomised controlled trials compared
with cohort studies is that the random allocation pro-
cess enhances the internal validity of a study by
minimising selection bias and confounding.6 This
paper relies on the definitions provided by CONSORT
(box 1).7
Allocation by chance in a randomised controlled
trial should mean that the groups being compared are
similar in terms of both measured and unmeasured
baseline factors.8 This is not so in cohort studies, and
therefore cohort studies are vulnerable to selection
bias. In cohort studies, factors that determined whether
a person received the intervention could result in the
groups differing in factors related to the outcome,
either because people were preferentially selected to
receive one treatment or because of choices that they
made. These baseline differences in prognosis could
confound the assessment of the effect of the interven-
tion.
In cohort studies care must be taken to minimise,
assess, and deal with selection bias. A comprehensive
Cohort studies can use diverse populations
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approach is needed that includes the selection of
appropriate comparison groups, the identification and
assessment of the comparability of potential confound-
ers between those comparison groups, and the use of
sophisticated statistical techniques in the analysis.
Comparison groups in cohort studies
The essence of any cohort study is the comparison of
outcomes between people who received the interven-
tion and those who did not. For example, to answer the
question, “Do patients who receive an atypical antipsy-
chotic drug have an increased risk of hip fracture?” a
cohort study must ask: “What would have happened to
these patients if they had not received the atypical
antipsychotic drug?”
Ideally, the comparison group in the cohort study
should be identical to the intervention group, apart
from the fact that they did not receive the intervention.
This ideal comparison group is described by
methodologists as providing the “counterfactual” or
“potential outcome.”9 In reality, this ideal comparison
group does not exist. Part of the art of designing a
cohort study is choosing comparison groups that
approach this ideal in order to minimise selection bias
while maintaining clinically relevance.
The analysis of the association between antipsy-
chotic drugs and hip fracture can be used to define the
types of comparisons that could be found in cohort
studies. For any specific intervention (such as exposure
to atypical antipsychotics) two factors—the exposure
experience of the comparison group and the
population from which the intervention and compari-
son groups are selected—define the types of compari-
sons that are possible (box 2). People taking atypical
antipsychotics can be compared with either people
taking an alternative antipsychotic or with those
prescribed no antipsychotic drugs. These comparisons
could be made in a general population (all elderly
people) or in a restricted population (elderly people
with dementia).
Questions to ask when assessing a
cohort study design
What comparison is being made?
Published studies may include more than one type of
comparison, but the focus of any appraisal of a cohort
study is on an individual comparison between an inter-
vention group and a comparison group in a defined
population. A well written study should contain a clear
definition of why the two groups were selected and
how they were defined. This information is essential
for assessment of clinical relevance and potential for
selection bias.
Does the comparison make clinical sense?
The clinical relevance of comparisons needs to be
assessed for each case. In the analysis of antipsychotic
use and hip fracture, for instance, all four types of com-
parison might be relevant. However, this might not be
true in other analyses. For example, although it would
be possible for a cohort study to compare HIV positive
patients receiving antiretroviral therapy with those
receiving no intervention,10 this comparison would be
irrelevant to many clinicians. A more relevant cohort
study would compare patients receiving one antiretro-
viral therapy with patients receiving another interven-
tion.11 In contrast, a clinically relevant study of the
adverse effects of a commonly used treatment such as
a non-steroidal anti-inflammatory drug might include
a comparison with a no intervention population since
no drug treatment could be a realistic option for some
people.12
Cohort studies should not only describe the popu-
lations being compared but also include a discussion of
the clinical context for that comparison and provide a
justification for the comparison. Readers of these
studies should determine if the study makes a
comparison that is realistic and relevant to their
decision needs.
Table 1 Comparison of cohort studies and randomised controlled trials
Item Cohort studies Randomised controlled trials
Populations studied Diverse populations of patients who are observed in a range of
settings
Highly selected populations recruited on the basis of detailed
criteria and treated at selected sites
Allocation to the intervention Based on decisions made by providers or patients Based on chance and controlled by investigators
Outcomes Can be defined after the intervention and can include rare or
unexpected events
Primary outcomes are determined before patients are entered
into study and are focused on predicted benefits and risks
Follow-up Many cohort studies rely on existing experience (retrospective
studies) and can provide an opportunity for long follow-up
Prospective studies; often have short follow-up because of
costs and pressure to produce timely evidence
Analysis Sophisticated multivariate techniques may be required to deal
with confounding
Analysis is straightforward
Box 1: CONSORT definitions of selection bias
and confounding7
Selection bias—a systematic error in creating
intervention groups, causing them to differ with
respect to prognosis. The groups differ in measured or
unmeasured baseline characteristics because of the
way in which participants were selected for the study
or assigned to their study groups
Confounding—a situation in which the estimated
intervention effect is biased because of some
difference between the comparison groups apart from
the planned interventions such as baseline
characteristics, prognostic factors, or concomitant
interventions. For a factor to be a confounder, it must
differ between the comparison groups and predict the
outcome of interest
Box 2: Possible types of comparisons in cohort
study
General population
1 Intervention v alternative intervention
2 Intervention v no intervention
Restricted population
3 Intervention v alternative intervention
4 Intervention v no intervention
Education and debate
Department of
Health Policy,
Management, and
Evaluation, Faculty
of Medicine,
University of
Toronto, Toronto,
ON, Canada
Geoffrey M
Anderson
chair in health
management
strategies
Correspondence to:
G M Anderson,
Institute for Clinical
Evaluative Sciences,
2075 Bayview
Avenue, Toronto,
ON M4N 3M5,
Canada
geoff.anderson@
utoronto.ca
896 BMJ VOLUME 330 16 APRIL 2005 bmj.com
What are the potential selection biases?
Selection bias occurs when there is something
inherently different between the groups being com-
pared that could explain differences in the observed
outcomes. One powerful strategy to minimise selection
bias is to restrict inclusion in the study to those with a
defined diagnosis or specific characteristics.3 Restrict-
ing the groups to a specific characteristic removes the
potential for bias related to that characteristic and can
reduce differences in related characteristics. Table 2
presents data from a cohort of older adults given atypi-
cal antipsychotics and a no intervention comparison
group. Patients taking atypical antipsychotics were over
12 times more likely (63.1% v 4.7%) to have dementia.
Dementia is related to the risk of hip fracture, and this
imbalance may be an important source of confound-
ing. Restricting the study to people with dementia
eliminates this source of confounding and reduces
selection related to age as the mean age difference
between the groups dropped from years to months.
An inevitable consequence of restriction is reduced
sample size. In the example, the sample decreased
from 1.3 million to about 80 000 when the dementia
restriction was applied. When smaller databases are
being used, restriction can greatly limit the power of
the study. Restriction on the basis of clinical character-
istics limits the generalisability of the findings. The
more restrictive the population, the less generalisable
the results.
It is important to keep in mind the effect the choice
of comparison groups will have on potential selection
bias when evaluating a cohort study. Some sources of
selection bias are clear—for example, if access to atypical
antipsychotics was limited to patients of specialists this
could result in patients who received these drugs being
different from those who did not. Some sources of bias
may bemore subtle. For example, if doctors thought that
atypical antipsychotics had fewer side effects than typical
antipsychotics, they might preferentially use the atypical
antipsychotics in frailer patients. This form of selection
bias, referred to as channelling bias or confounding by
indication,13 occurs when patients are assigned to one
intervention or another on the basis of prognostic
factors and is key issue in cohort studies.
Readers should recognise the potential for
selection bias in all cohort studies and carefully
consider possible sources of bias. In the next article we
will outline the link between selection bias and
confounding and describe a strategy for identifying
and assessing the potential for confounding.
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Table 2 Effect on age distribution and sample size of restricting comparison of atypical antipsychotic with no intervention to
individuals with dementia
All older people Older people with dementia
Atypical antipsychotic (n=34 960) No Intervention (n=1 251 435) Atypical antipsychotic (n=21 427) No intervention (n=58 754)
Mean (SD) age 80.46 (7.63) 74.50 (6.58) 81.69 (7.11) 80.95 (7.64)
No (%) with
dementia
21 427 (61.3) 58 754 (4.7) 21 427 (100) 58 754 (100)
Key questions
What comparison is being made?
Does the comparison make clinical sense?
What are the potential selection biases?
Endpiece
Good advice
Better to hunt in fields, for health unbought,
Than fee the doctor for a nauseous draught.
The wise, for cure, on exercise depend;
God never made his work for man to mend.
John Dryden (1631-1700) in Epistle to John
Driden of Chesterton (1700)
Fred Charatan, retired geriatric physician, Florida
Education and debate
897BMJ VOLUME 330 16 APRIL 2005 bmj.com
